Palvella Therapeutics (PVLA) Receivables (2013 - 2024)

Palvella Therapeutics (PVLA) has 12 years of Receivables data on file, last reported at $358000.0 in Q4 2024.

• On a quarterly basis, Receivables fell 84.61% year-over-year to $358000.0 in Q4 2024; TTM through Dec 2024 was $358000.0, a 84.61% decrease from a year earlier, with the FY2024 full-year figure at $358000.0, down 84.61% from the prior year.
• Receivables for Q4 2024 stood at $358000.0, down from $879000.0 in the prior quarter.
• Over the last five years, Receivables for PVLA reached as high as $15.8 million in Q1 2021 and fell as low as $358000.0 in Q4 2024.
• Historically, Receivables has averaged $3.7 million across 5 years, with a median of $2.0 million in 2020.
• Across the five-year window, Receivables tumbled 89.6% in 2022 and soared 295.64% in 2024, its largest moves.
• Year by year, Receivables stood at $1.7 million in 2020, then soared by 94.2% to $3.3 million in 2021, then jumped by 89.31% to $6.3 million in 2022, then sank by 62.91% to $2.3 million in 2023, then slumped by 84.61% to $358000.0 in 2024.
• Per Business Quant data, the three most recent Receivables figures were $358000.0 in Q4 2024, $879000.0 in Q3 2024, and $1.6 million in Q2 2024.